Global AI for Drug Discovery Market
Global AI for Drug Discovery Market

AI for Drug Discovery Comprehensive Study by Drug Type (Small Molecule, Large Molecules), Therapeutic Type (Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Others), Technology (Deep Learning, Machine Learning), End User (Pharmaceutical Companies, Biopharmaceutical Companies, Academic and Research Institutes, Others) Players and Region - Global Market Outlook to 2024

AI for Drug Discovery Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jun 2019 Edition 222 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
Rapid growth in cases of rare diseases, as well as demand for a personalized drug, will help to boost global AI for the drug discovery market. Artificial intelligence (AI) for drug discovery is a technology that uses and different algorithms that value add in decision-making procedures for drug discovery. This technology has the ability to identify drug targets and play a vital role in drug discovery, design, identification, and screening of molecules instantly and effectively. Growing demand in the untapped market will help to fuel market demand.

The market study is being classified and major geographies with country level break-up.

Atomwise, Inc. (United States), Insilico Medicine (United States), BIOAGE (United States), Envisagenics (New York), Cloud Pharmaceuticals, Inc. (United States), Numerate (United States), NuMedii, Inc. (United States), BenevolentAI (United Kingdom), twoXAR, Incorporated (United States) and Exscientia (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Globavir, Inc. (United States) and Tute Genomics (PierianDx, Inc.) (United States).

The Players having a strong hold in the market are Atomwise, Inc.. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global AI for Drug Discovery market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global AI for Drug Discovery market by Type, Application and Region.

On the basis of geography, the market of AI for Drug Discovery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Drug Type, the sub-segment i.e. Small Molecule will boost the AI for Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic Type, the sub-segment i.e. Metabolic Disease will boost the AI for Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Deep Learning will boost the AI for Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Pharmaceutical Companies will boost the AI for Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Demand Due To Reduction in Price
  • High Adoption Due To AI Reduces Researches and Development Gap in the Drug Manufacturing Process

Market Trend
  • Growing Number of Cross-Industry Partnerships & Collaborations
  • Upsurge In Capital of the R&D Activities for the Use of AI Technology

Restraints
  • High Cost and Technical Limitations

Opportunities
  • Rising Awareness about AI for Drug Discovery
  • Huge Demand from Untapped Market

Challenges
  • Reluctance among Medical Practitioners to Adopt AI-Based Technologies


Market Leaders and their expansionary development strategies
On 16th April 2019, Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization working to deliver new treatments for neglected diseases has launched promising drug-like compounds have been discovered in a program to develop first-in-class treatments for Chagas disease. The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program.
On 30th May 2018, Cloud Pharmaceuticals, Inc., an Artificial Intelligence-driven drug design and Development Company has collaborated with GlaxoSmithKline (GSK). Cloud will design novel small-molecule agents to GSK specified targets. Cloud will use its proprietary AI-driven process to design the molecules.


Key Target Audience
AI for Drug Discovery Providers, Pharmaceutical Companies, Medical Associations, Technology Developers, Government Regulatory Bodies, Private and Government Research Organizations and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Drug Type
  • Small Molecule
  • Large Molecules

By Therapeutic Type
  • Metabolic Disease
  • Cardiovascular Disease
  • Oncology
  • Neurodegenerative Diseases
  • Others

By Technology
  • Deep Learning
  • Machine Learning

By End User
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand Due To Reduction in Price
      • 3.2.2. High Adoption Due To AI Reduces Researches and Development Gap in the Drug Manufacturing Process
    • 3.3. Market Challenges
      • 3.3.1. Reluctance among Medical Practitioners to Adopt AI-Based Technologies
    • 3.4. Market Trends
      • 3.4.1. Growing Number of Cross-Industry Partnerships & Collaborations
      • 3.4.2. Upsurge In Capital of the R&D Activities for the Use of AI Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global AI for Drug Discovery, by Drug Type, Therapeutic Type, Technology, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global AI for Drug Discovery (Value)
      • 5.2.1. Global AI for Drug Discovery by: Drug Type (Value)
        • 5.2.1.1. Small Molecule
        • 5.2.1.2. Large Molecules
      • 5.2.2. Global AI for Drug Discovery by: Therapeutic Type (Value)
        • 5.2.2.1. Metabolic Disease
        • 5.2.2.2. Cardiovascular Disease
        • 5.2.2.3. Oncology
        • 5.2.2.4. Neurodegenerative Diseases
        • 5.2.2.5. Others
      • 5.2.3. Global AI for Drug Discovery by: Technology (Value)
        • 5.2.3.1. Deep Learning
        • 5.2.3.2. Machine Learning
      • 5.2.4. Global AI for Drug Discovery by: End User (Value)
        • 5.2.4.1. Pharmaceutical Companies
        • 5.2.4.2. Biopharmaceutical Companies
        • 5.2.4.3. Academic and Research Institutes
        • 5.2.4.4. Others
      • 5.2.5. Global AI for Drug Discovery Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. AI for Drug Discovery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Atomwise, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Insilico Medicine (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BIOAGE (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Envisagenics (New York)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cloud Pharmaceuticals, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Numerate (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. NuMedii, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BenevolentAI (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. TwoXAR, Incorporated (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Exscientia (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global AI for Drug Discovery Sale, by Drug Type, Therapeutic Type, Technology, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global AI for Drug Discovery (Value)
      • 7.2.1. Global AI for Drug Discovery by: Drug Type (Value)
        • 7.2.1.1. Small Molecule
        • 7.2.1.2. Large Molecules
      • 7.2.2. Global AI for Drug Discovery by: Therapeutic Type (Value)
        • 7.2.2.1. Metabolic Disease
        • 7.2.2.2. Cardiovascular Disease
        • 7.2.2.3. Oncology
        • 7.2.2.4. Neurodegenerative Diseases
        • 7.2.2.5. Others
      • 7.2.3. Global AI for Drug Discovery by: Technology (Value)
        • 7.2.3.1. Deep Learning
        • 7.2.3.2. Machine Learning
      • 7.2.4. Global AI for Drug Discovery by: End User (Value)
        • 7.2.4.1. Pharmaceutical Companies
        • 7.2.4.2. Biopharmaceutical Companies
        • 7.2.4.3. Academic and Research Institutes
        • 7.2.4.4. Others
      • 7.2.5. Global AI for Drug Discovery Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. AI for Drug Discovery: by Drug Type(USD Million)
  • Table 2. AI for Drug Discovery Small Molecule , by Region USD Million (2013-2018)
  • Table 3. AI for Drug Discovery Large Molecules , by Region USD Million (2013-2018)
  • Table 4. AI for Drug Discovery: by Therapeutic Type(USD Million)
  • Table 5. AI for Drug Discovery Metabolic Disease , by Region USD Million (2013-2018)
  • Table 6. AI for Drug Discovery Cardiovascular Disease , by Region USD Million (2013-2018)
  • Table 7. AI for Drug Discovery Oncology , by Region USD Million (2013-2018)
  • Table 8. AI for Drug Discovery Neurodegenerative Diseases , by Region USD Million (2013-2018)
  • Table 9. AI for Drug Discovery Others , by Region USD Million (2013-2018)
  • Table 10. AI for Drug Discovery: by Technology(USD Million)
  • Table 11. AI for Drug Discovery Deep Learning , by Region USD Million (2013-2018)
  • Table 12. AI for Drug Discovery Machine Learning , by Region USD Million (2013-2018)
  • Table 13. AI for Drug Discovery: by End User(USD Million)
  • Table 14. AI for Drug Discovery Pharmaceutical Companies , by Region USD Million (2013-2018)
  • Table 15. AI for Drug Discovery Biopharmaceutical Companies , by Region USD Million (2013-2018)
  • Table 16. AI for Drug Discovery Academic and Research Institutes , by Region USD Million (2013-2018)
  • Table 17. AI for Drug Discovery Others , by Region USD Million (2013-2018)
  • Table 18. South America AI for Drug Discovery, by Country USD Million (2013-2018)
  • Table 19. South America AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 20. South America AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 21. South America AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 22. South America AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 23. Brazil AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 24. Brazil AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 25. Brazil AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 26. Brazil AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 27. Argentina AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 28. Argentina AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 29. Argentina AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 30. Argentina AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 31. Rest of South America AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 32. Rest of South America AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 33. Rest of South America AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 34. Rest of South America AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 35. Asia Pacific AI for Drug Discovery, by Country USD Million (2013-2018)
  • Table 36. Asia Pacific AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 37. Asia Pacific AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 38. Asia Pacific AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 39. Asia Pacific AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 40. China AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 41. China AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 42. China AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 43. China AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 44. Japan AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 45. Japan AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 46. Japan AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 47. Japan AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 48. India AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 49. India AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 50. India AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 51. India AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 52. South Korea AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 53. South Korea AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 54. South Korea AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 55. South Korea AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 56. Taiwan AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 57. Taiwan AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 58. Taiwan AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 59. Taiwan AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 60. Australia AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 61. Australia AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 62. Australia AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 63. Australia AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 64. Rest of Asia-Pacific AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 68. Europe AI for Drug Discovery, by Country USD Million (2013-2018)
  • Table 69. Europe AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 70. Europe AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 71. Europe AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 72. Europe AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 73. Germany AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 74. Germany AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 75. Germany AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 76. Germany AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 77. France AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 78. France AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 79. France AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 80. France AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 81. Italy AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 82. Italy AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 83. Italy AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 84. Italy AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 85. United Kingdom AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 86. United Kingdom AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 87. United Kingdom AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 88. United Kingdom AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 89. Netherlands AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 90. Netherlands AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 91. Netherlands AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 92. Netherlands AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 93. Rest of Europe AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 94. Rest of Europe AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 95. Rest of Europe AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 96. Rest of Europe AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 97. MEA AI for Drug Discovery, by Country USD Million (2013-2018)
  • Table 98. MEA AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 99. MEA AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 100. MEA AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 101. MEA AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 102. Middle East AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 103. Middle East AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 104. Middle East AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 105. Middle East AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 106. Africa AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 107. Africa AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 108. Africa AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 109. Africa AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 110. North America AI for Drug Discovery, by Country USD Million (2013-2018)
  • Table 111. North America AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 112. North America AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 113. North America AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 114. North America AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 115. United States AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 116. United States AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 117. United States AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 118. United States AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 119. Canada AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 120. Canada AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 121. Canada AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 122. Canada AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 123. Mexico AI for Drug Discovery, by Drug Type USD Million (2013-2018)
  • Table 124. Mexico AI for Drug Discovery, by Therapeutic Type USD Million (2013-2018)
  • Table 125. Mexico AI for Drug Discovery, by Technology USD Million (2013-2018)
  • Table 126. Mexico AI for Drug Discovery, by End User USD Million (2013-2018)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. AI for Drug Discovery: by Drug Type(USD Million)
  • Table 138. AI for Drug Discovery Small Molecule , by Region USD Million (2019-2024)
  • Table 139. AI for Drug Discovery Large Molecules , by Region USD Million (2019-2024)
  • Table 140. AI for Drug Discovery: by Therapeutic Type(USD Million)
  • Table 141. AI for Drug Discovery Metabolic Disease , by Region USD Million (2019-2024)
  • Table 142. AI for Drug Discovery Cardiovascular Disease , by Region USD Million (2019-2024)
  • Table 143. AI for Drug Discovery Oncology , by Region USD Million (2019-2024)
  • Table 144. AI for Drug Discovery Neurodegenerative Diseases , by Region USD Million (2019-2024)
  • Table 145. AI for Drug Discovery Others , by Region USD Million (2019-2024)
  • Table 146. AI for Drug Discovery: by Technology(USD Million)
  • Table 147. AI for Drug Discovery Deep Learning , by Region USD Million (2019-2024)
  • Table 148. AI for Drug Discovery Machine Learning , by Region USD Million (2019-2024)
  • Table 149. AI for Drug Discovery: by End User(USD Million)
  • Table 150. AI for Drug Discovery Pharmaceutical Companies , by Region USD Million (2019-2024)
  • Table 151. AI for Drug Discovery Biopharmaceutical Companies , by Region USD Million (2019-2024)
  • Table 152. AI for Drug Discovery Academic and Research Institutes , by Region USD Million (2019-2024)
  • Table 153. AI for Drug Discovery Others , by Region USD Million (2019-2024)
  • Table 154. South America AI for Drug Discovery, by Country USD Million (2019-2024)
  • Table 155. South America AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 156. South America AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 157. South America AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 158. South America AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 159. Brazil AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 160. Brazil AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 161. Brazil AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 162. Brazil AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 163. Argentina AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 164. Argentina AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 165. Argentina AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 166. Argentina AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 167. Rest of South America AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 168. Rest of South America AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 169. Rest of South America AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 170. Rest of South America AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 171. Asia Pacific AI for Drug Discovery, by Country USD Million (2019-2024)
  • Table 172. Asia Pacific AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 173. Asia Pacific AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 174. Asia Pacific AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 175. Asia Pacific AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 176. China AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 177. China AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 178. China AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 179. China AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 180. Japan AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 181. Japan AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 182. Japan AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 183. Japan AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 184. India AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 185. India AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 186. India AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 187. India AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 188. South Korea AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 189. South Korea AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 190. South Korea AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 191. South Korea AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 192. Taiwan AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 193. Taiwan AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 194. Taiwan AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 195. Taiwan AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 196. Australia AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 197. Australia AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 198. Australia AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 199. Australia AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 200. Rest of Asia-Pacific AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 201. Rest of Asia-Pacific AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 202. Rest of Asia-Pacific AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 203. Rest of Asia-Pacific AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 204. Europe AI for Drug Discovery, by Country USD Million (2019-2024)
  • Table 205. Europe AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 206. Europe AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 207. Europe AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 208. Europe AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 209. Germany AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 210. Germany AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 211. Germany AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 212. Germany AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 213. France AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 214. France AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 215. France AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 216. France AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 217. Italy AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 218. Italy AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 219. Italy AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 220. Italy AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 221. United Kingdom AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 222. United Kingdom AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 223. United Kingdom AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 224. United Kingdom AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 225. Netherlands AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 226. Netherlands AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 227. Netherlands AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 228. Netherlands AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 229. Rest of Europe AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 230. Rest of Europe AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 231. Rest of Europe AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 232. Rest of Europe AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 233. MEA AI for Drug Discovery, by Country USD Million (2019-2024)
  • Table 234. MEA AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 235. MEA AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 236. MEA AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 237. MEA AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 238. Middle East AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 239. Middle East AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 240. Middle East AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 241. Middle East AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 242. Africa AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 243. Africa AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 244. Africa AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 245. Africa AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 246. North America AI for Drug Discovery, by Country USD Million (2019-2024)
  • Table 247. North America AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 248. North America AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 249. North America AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 250. North America AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 251. United States AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 252. United States AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 253. United States AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 254. United States AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 255. Canada AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 256. Canada AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 257. Canada AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 258. Canada AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 259. Mexico AI for Drug Discovery, by Drug Type USD Million (2019-2024)
  • Table 260. Mexico AI for Drug Discovery, by Therapeutic Type USD Million (2019-2024)
  • Table 261. Mexico AI for Drug Discovery, by Technology USD Million (2019-2024)
  • Table 262. Mexico AI for Drug Discovery, by End User USD Million (2019-2024)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global AI for Drug Discovery: by Drug Type USD Million (2013-2018)
  • Figure 5. Global AI for Drug Discovery: by Therapeutic Type USD Million (2013-2018)
  • Figure 6. Global AI for Drug Discovery: by Technology USD Million (2013-2018)
  • Figure 7. Global AI for Drug Discovery: by End User USD Million (2013-2018)
  • Figure 8. South America AI for Drug Discovery Share (%), by Country
  • Figure 9. Asia Pacific AI for Drug Discovery Share (%), by Country
  • Figure 10. Europe AI for Drug Discovery Share (%), by Country
  • Figure 11. MEA AI for Drug Discovery Share (%), by Country
  • Figure 12. North America AI for Drug Discovery Share (%), by Country
  • Figure 13. Global AI for Drug Discovery share by Players 2018 (%)
  • Figure 14. Global AI for Drug Discovery share by Players (Top 3) 2018(%)
  • Figure 15. Global AI for Drug Discovery share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Atomwise, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Atomwise, Inc. (United States) Revenue: by Geography 2018
  • Figure 19. Insilico Medicine (United States) Revenue, Net Income and Gross profit
  • Figure 20. Insilico Medicine (United States) Revenue: by Geography 2018
  • Figure 21. BIOAGE (United States) Revenue, Net Income and Gross profit
  • Figure 22. BIOAGE (United States) Revenue: by Geography 2018
  • Figure 23. Envisagenics (New York) Revenue, Net Income and Gross profit
  • Figure 24. Envisagenics (New York) Revenue: by Geography 2018
  • Figure 25. Cloud Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Cloud Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Numerate (United States) Revenue, Net Income and Gross profit
  • Figure 28. Numerate (United States) Revenue: by Geography 2018
  • Figure 29. NuMedii, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. NuMedii, Inc. (United States) Revenue: by Geography 2018
  • Figure 31. BenevolentAI (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. BenevolentAI (United Kingdom) Revenue: by Geography 2018
  • Figure 33. TwoXAR, Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 34. TwoXAR, Incorporated (United States) Revenue: by Geography 2018
  • Figure 35. Exscientia (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. Exscientia (United Kingdom) Revenue: by Geography 2018
  • Figure 37. Global AI for Drug Discovery: by Drug Type USD Million (2019-2024)
  • Figure 38. Global AI for Drug Discovery: by Therapeutic Type USD Million (2019-2024)
  • Figure 39. Global AI for Drug Discovery: by Technology USD Million (2019-2024)
  • Figure 40. Global AI for Drug Discovery: by End User USD Million (2019-2024)
  • Figure 41. South America AI for Drug Discovery Share (%), by Country
  • Figure 42. Asia Pacific AI for Drug Discovery Share (%), by Country
  • Figure 43. Europe AI for Drug Discovery Share (%), by Country
  • Figure 44. MEA AI for Drug Discovery Share (%), by Country
  • Figure 45. North America AI for Drug Discovery Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Atomwise, Inc. (United States)
  • Insilico Medicine (United States)
  • BIOAGE (United States)
  • Envisagenics (New York)
  • Cloud Pharmaceuticals, Inc. (United States)
  • Numerate (United States)
  • NuMedii, Inc. (United States)
  • BenevolentAI (United Kingdom)
  • twoXAR, Incorporated (United States)
  • Exscientia (United Kingdom)
Additional players considered in the study are as follows:
Globavir, Inc. (United States) , Tute Genomics (PierianDx, Inc.) (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation